Johnson & Johnson — TREMFYA (guselkumab) · Active psoriatic arthritis.
Run-up into the decision (T-120 → T+5)
Daily close, T-120 (12/12/25) through T+5. Run-up high $248.56 on 3/4/26, low $199.96 on 12/17/25 (T-120 to T-1). FDA decision 5/29/26. Historical price action, not a forecast.